Digital Look

Welcome to Digital Look++,
you are not logged in

AbbVie Inc (ABBV)

$ 171.73

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-19	33,266.00	8,426.00	530.00¢	16.7	0.4	+44%	439.00¢	5.0%
31-Dec-20	45,804.00	3,398.00	273.00¢	39.2	n/a	-48%	484.00¢	4.5%
31-Dec-21	56,197.00	12,989.00	648.00¢	20.9	0.2	+137%	531.00¢	3.9%
31-Dec-22	58,054.00	13,477.00	665.00¢	24.3	8.1	+3%	571.00¢	3.5%
31-Dec-23	54,318.00	6,250.00	273.00¢	56.8	n/a	-59%	599.00¢	3.9%

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-24	56,062.91	24,659.74	1,094.50¢	15.7	0.1	+301%	623.34¢	0.0%
31-Dec-25	59,213.17	27,565.90	1,212.13¢	14.2	1.3	+11%	653.34¢	0.0%
31-Dec-26	63,608.32	30,660.34	1,364.78¢	12.6	1.0	+13%	678.07¢	0.0%

AstraZeneca sells hypertension drug rights; End...	27-Jan-2020	ShareCast
Botox maker Allergan reports jump in third-quart...	05-Nov-2019	ShareCast
Abbvie snaps up Botox-maker Allergan in $63bn deal	25-Jun-2019	ShareCast

Abbvie boss blasts US tax regime	21-Oct-2014	Telegraph
Drug company AbbVie takeover rival in £31bn bid	18-Jul-2014	Express & Star
AbbVie to announce firm bid for Shire	18-Jul-2014	Telegraph

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Forecast figures based on normalised accounts.